Authors: Brouard, R Bossmar, T Fournie-Lloret, D Chassard, D Akerlund, M

Citation: R. Brouard et al., Effect of SR49059, an orally active V-1a vasopressin receptor antagonist, in the prevention of dysmenorrhoea, BR J OBST G, 107(5), 2000, pp. 614-619

Authors: Hayoz, D Bizzini, G Noel, B Depairon, M Burnier, M Fauveau, C Rouillon, A Brouard, R Brunner, HR

Citation: D. Hayoz et al., Effect of SR 49059, a V1a vasopressin receptor antagonist, in Raynand's phenomenon, RHEUMATOLOG, 39(10), 2000, pp. 1132-1138

Authors: Akerlund, M Bossmar, T Brouard, R Kostrzewska, A Laudanski, T Lemancewicz, A Serradeil-Le Gal, C Steinwall, M

Citation: M. Akerlund et al., Receptor binding of oxytocin and vasopressin antagonists and inhibitory effects on isolated myometrium from preterm and term pregnant women, BR J OBST G, 106(10), 1999, pp. 1047-1053

Authors: Thibonnier, M Kilani, A Rahman, M DiBlasi, TP Warner, K Smith, MC Leenhardt, AF Brouard, R

Citation: M. Thibonnier et al., Effects of the nonpeptide V-1 vasopressin receptor antagonist SR49059 in hypertensive patients, HYPERTENSIO, 34(6), 1999, pp. 1293-1300

Authors: Funck-Brentano, C Brouard, R

Citation: C. Funck-brentano et R. Brouard, How can our institutions optimize clinical research in France?, THERAPIE, 54(4), 1999, pp. 479-484